Results 141 to 150 of about 46,296 (214)

Targeting the <i>ZMYM2-ANXA9</i> Axis: Organoid Models Illuminate a Novel Pathway to Overcome Oxaliplatin Resistance in Colorectal Cancer. [PDF]

Biomedicines
Zeng SJ, He K, Shi Z.
europepmc   +1 more source

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer. [PDF]

Cancer Drug Resist
Xu Z, Sun S, Gao H, Feng R, Shen X.
europepmc   +1 more source

Correction: An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. [PDF]

Oncol Rep
Röttgen H, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, Neoptolemos JP, Köberle B, Theile D.   +8 more
europepmc   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11
Background: Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC.
openaire  

Cigarette smoke extract promotes metastasis and oxaliplatin resistance in colon adenocarcinoma through GDF15/ERBB2/AKT pathway. [PDF]

Eur J Med Res
Jiang W, Wang Y, Wang WJ, Zhou BC, Hu XS, Xu AM.   +5 more
europepmc   +1 more source

An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. [PDF]

BMC Gastroenterol
Liao X, Liu M, Hong C, Liu Y, Li Q, Chen Y, Zhang T, Chen H, Fu S.   +8 more
europepmc   +1 more source

Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Hussain MS, Jakhmola V, Goyal K, Rekha A, Sultana A, Ali H, Gupta G.   +6 more
europepmc   +1 more source

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis. [PDF]

Biology (Basel)
Long M, Ouyang Q, Wen J, Zeng X, Xu Z, Zhong S, Huang C, Luo JL.   +7 more
europepmc   +1 more source